The DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.
Molecular aspects of cancer cell resistance to chemotherapy
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
The DNA Damage Response: Making It Safe to Play with Knives
Ciccia, A., & Elledge, S. J. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.019 · Cited by 4,368
Tumour stem cells and drug resistance
Dean, M., Fojo, T., & Bates, S. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1590 · Cited by 3,668
Cisplatin: mode of cytotoxic action and molecular basis of resistance
Siddik, Z. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206933 · Cited by 3,335
Patterns of somatic mutation in human cancer genomes
Greenman, C., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G., Davies, H., Teague, J., Butler, A., Stevens, C., et al. (2007) · Nature · doi:10.1038/nature05610 · Cited by 3,080
Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability
Colotta, F., Allavena, P., Sica, A., Garlanda, C., & Mantovani, A. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp127 · Cited by 2,890
Molecular mechanisms of cisplatin resistance
Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., & Kroemer, G. (2012) · Oncogene · doi:10.1038/onc.2011.384 · Cited by 2,760 · cited 1×
“[54] and Siddik [55].”
Systematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456
Hypoxia in cancer: significance and impact on clinical outcome
Vaupel, P., & Mayer, A. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9055-1 · Cited by 2,240
Death and anti-death: tumour resistance to apoptosis
Igney, F. H., & Krammer, P. H. (2002) · Nature Reviews Cancer · doi:10.1038/nrc776 · Cited by 2,075
Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.022 · Cited by 1,858 · cited 1×
“More and more reports showed that PTEN plays a role in the response of cancer cells to oncoprotein targeting molecules: loss of PTEN leads to both primary and acquired increased resistance [18].”
BackgroundEfficient tumour formation by single human melanoma cells
Quintana, E., Shackleton, M., Sabel, M. S., Fullen, D. R., Johnson, T. M., & Morrison, S. J. (2008) · Nature · doi:10.1038/nature07567 · Cited by 1,796
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z. R., Du, J., Davis, A., Mongare, M. M., Gould, J., Frederick, D. T., et al. (2012) · Nature · doi:10.1038/nature11183 · Cited by 1,771
The unique physiology of solid tumors: opportunities (and problems) for cancer therapy.
Brown, J. M., & Giaccia, A. J. (1998) · PubMed · Cited by 1,748
DeNardo, D. G., Brennan, D. J., Rexhepaj, E., Ruffell, B., Shiao, S. L., Madden, S. F., Gallagher, W. M., Wadhwani, N., Keil, S. D., Junaid, S. A., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-10-0028 · Cited by 1,715
The DNA damage response and cancer therapy
Lord, C. J., & Ashworth, A. (2012) · Nature · doi:10.1038/nature10760 · Cited by 1,649
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikakos, P. I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., Moriceau, G., Shi, H., Atefi, M., Titz, B., Gabay, M. T., et al. (2011) · Nature · doi:10.1038/nature10662 · Cited by 1,454
The impact of O2 availability on human cancer
Bertout, J. A., Patel, S. A., & Simon, M. C. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2540 · Cited by 1,365
PTEN and the PI3-Kinase Pathway in Cancer
Chalhoub, N., & Baker, S. J. (2009) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.4.110807.092311 · Cited by 1,245
Life and death partners: apoptosis, autophagy and the cross-talk between them
Eisenberg-Lerner, A., Bialik, S., Simon, H.-U., & Kimchi, A. (2009) · Cell Death & Differentiation · doi:10.1038/cdd.2009.33 · Cited by 1,183
Roesch, A., Fukunaga-Kalabis, M., Schmidt, E. C., Zabierowski, S. E., Brafford, P. A., Vultur, A., Basu, D., Gimotty, P., Vogt, T., & Herlyn, M. (2010) · Cell · doi:10.1016/j.cell.2010.04.020 · Cited by 1,158
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
Wilson, T. R., Fridlyand, J., Yan, Y., Penuel, E., Burton, L., Chan, E., Peng, J., Lin, E., Wang, Y., Sosman, J., et al. (2012) · Nature · doi:10.1038/nature11249 · Cited by 1,134 · cited 1×
“Finally, tumor cells may also hijack stromal cells to secrete growth factors like HGF that will compensate for their inhibited addiction pathway in a paracrine manner [73,74].”
BackgroundMicrotubules and resistance to tubulin-binding agents
Kavallaris, M. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2803 · Cited by 1,120
DNA repair dysregulation from cancer driver to therapeutic target
Curtin, N. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3399 · Cited by 1,051
Disruption of p53 in human cancer cells alters the responses to therapeutic agents.
Bunz, F., Hwang, P. M., Torrance, C., Waldman, T., Zhang, Y., Dillehay, L., Williams, J., Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6863 · Cited by 1,044
O'Hare, T., Walters, D. K., Stoffregen, E. P., Jia, T., Manley, P. W., Mestan, J., Cowan-Jacob, S. W., Lee, F. Y., Heinrich, M. C., Deininger, M. W. N., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0259 · Cited by 1,036
Environment-mediated drug resistance: A major contributor to minimal residual disease
Meads, M. B., Gatenby, R. A., & Dalton, W. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2714 · Cited by 892
Complex landscapes of somatic rearrangement in human breast cancer genomes
Stephens, P. J., McBride, D. J., Lin, M.-L., Varela, I., Pleasance, E. D., Simpson, J. T., Stebbings, L. A., Leroy, C., Edkins, S., Mudie, L. J., et al. (2009) · Nature · doi:10.1038/nature08645 · Cited by 845
Tumour-initiating cells: challenges and opportunities for anticancer drug discovery
Zhou, B.-B. S., Zhang, H., Damelin, M., Geles, K. G., Grindley, J. C., & Dirks, P. B. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2137 · Cited by 841
Sun, Y., Campisi, J., Higano, C., Beer, T. M., Porter, P., Coleman, I., True, L., & Nelson, P. S. (2012) · Nature Medicine · doi:10.1038/nm.2890 · Cited by 793 · cited 3×
“Cancer-associated fibroblasts (CAFs) make the bulk of the cancer stroma [81].”
BackgroundDe Luca, A., Maiello, M. R., D'Alessio, A., Pergameno, M., & Normanno, N. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.639361 · Cited by 735
Apoptosis and cancer: mutations within caspase genes
Ghavami, S., Hashemi, M., Ande, S. R., Yeganeh, B., Xiao, W., Eshraghi, M., Bus, C. J., Kadkhoda, K., Wiechec, E., Halayko, A. J., et al. (2009) · Journal of Medical Genetics · doi:10.1136/jmg.2009.066944 · Cited by 713
Cancer stem cell definitions and terminology: the devil is in the details
Valent, P., Bonnet, D., De Maria, R., Lapidot, T., Copland, M., Melo, J. V., Chomienne, C., Ishikawa, F., Schuringa, J. J., Stassi, G., et al. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3368 · Cited by 692
Stromal cells in tumor microenvironment and breast cancer
Mao, Y., Keller, E. T., Garfield, D. H., Shen, K., & Wang, J. (2013) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9415-3 · Cited by 671
The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance
Bouwman, P., & Jonkers, J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3342 · Cited by 615
Rohwer, N., & Cramer, T. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2011.03.001 · Cited by 608
Ng, K. P., Hillmer, A. M., Chuah, C. T. H., Juan, W. C., Ko, T. K., Teo, A. S. M., Ariyaratne, P. N., Takahashi, N., Sawada, K., Fei, Y., et al. (2012) · Nature Medicine · doi:10.1038/nm.2713 · Cited by 557
Taxanes, microtubules and chemoresistant breast cancer
McGrogan, B. T., Gilmartin, B., Carney, D. N., & McCann, A. (2008) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2007.10.004 · Cited by 535
NF-κB addiction and its role in cancer: ‘one size does not fit all’
Chaturvedi, M. M., Sung, B., Yadav, V. R., Kannappan, R., & Aggarwal, B. B. (2011) · Oncogene · doi:10.1038/onc.2010.566 · Cited by 473
Antifolates in cancer therapy: Structure, activity and mechanisms of drug resistance
Gonen, N., & Assaraf, Y. G. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.07.002 · Cited by 437
NF-κB and cancer: how intimate is this relationship
Prasad, S., Ravindran, J., & Aggarwal, B. B. (2010) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-009-0267-2 · Cited by 385
Tumor-associated macrophages: Effectors of angiogenesis and tumor progression
Coffelt, S. B., Hughes, R., & Lewis, C. E. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.02.004 · Cited by 355
Cosse, J.-P., & Michiels, C. (2008) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152008785914798 · Cited by 348 · cited 1×
“Metabolic changes, multidrug resistance protein overexpression, inhibition of apoptosis, induction of autophagy and inhibition of DDR are part of the cellular reprogramming triggered by HIFs that compromises the effectiveness of chemotherapy [78].”
BackgroundSelf-citationTailoring to RB: tumour suppressor status and therapeutic response
Knudsen, E. S., & Knudsen, K. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2401 · Cited by 344
Resistance to chemotherapy: new treatments and novel insights into an old problem
Raguz, S., & Yagüe, E. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604510 · Cited by 312
Chemoresistance of glioblastoma cancer stem cells - much more complex than expected
Beier, D., Schulz, J. B., & Beier, C. P. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-128 · Cited by 312
Cao, L., Xu, X., Bunting, S. F., Liu, J., Wang, R.-H., Cao, L. L., Wu, J. J., Peng, T.-N., Chen, J., Nussenzweig, A., et al. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.06.037 · Cited by 309
Paclitaxel Resistance in Non–Small-Cell Lung Cancer Associated With Beta-Tubulin Gene Mutations
Monzó, M., Rosell, R., Sánchez, J. J., Lee, J. S., O'Brate, A., González-Larriba, J. L., Alberola, V., Lorenzo, J. C., Núñez, L., Ro, J. Y., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.6.1786 · Cited by 306
Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia
Park, S., Chapuis, N., Tamburini, J., Bardet, V., Cornillet-Lefebvre, P., Willems, L., Green, A., Mayeux, P., Lacombe, C., & Bouscary, D. (2010) · Haematologica · doi:10.3324/haematol.2009.013797 · Cited by 306
Dysregulation of apoptotic signaling in cancer: Molecular mechanisms and therapeutic opportunities
Plati, J., Bucur, O., & Khosravi‐Far, R. (2008) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21707 · Cited by 293
Castells, M., Thibault, B., Delord, J.-P., & Couderc, B. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13089545 · Cited by 285
Batra, S. K., Castelino‐Prabhu, S., Wikstrand, C. J., Zhu, X., Humphrey, P. A., Friedman, H. S., & Bigner, D. D. (1995) · PubMed · Cited by 281
Dimberg, L. Y., Anderson, C. K., Camidge, R., Behbakht, K., Thorburn, A., & Ford, H. L. (2013) · Oncogene · doi:10.1038/onc.2012.164 · Cited by 276
Controlling escape from angiogenesis inhibitors
Sennino, B., & McDonald, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3366 · Cited by 264
The Emergence of Drug Transporter-Mediated Multidrug Resistance to Cancer Chemotherapy
Wu, C.-P., Hsieh, C.-H., & Wu, Y.-S. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200261n · Cited by 234
Borst, P. (2012) · Open Biology · doi:10.1098/rsob.120066 · Cited by 212
Molecular Pathways: Regulation and Therapeutic Implications of Multidrug Resistance
Chen, K. G., & Sikic, B. I. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1590 · Cited by 197
Developmental signaling pathways in cancer stem cells of solid tumors
Karamboulas, C., & Ailles, L. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2012.11.008 · Cited by 190
New Insight into P-Glycoprotein as a Drug Target
Breier, A., Gibalová, L., Šereš, M., Barančík, M., & Sulová, Z. (2012) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152013804487380 · Cited by 171
Autophagy as a mediator of chemotherapy-induced cell death in cancer
Notte, A., Leclere, L., & Michiels, C. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.06.015 · Cited by 166
Self-citationCancer Stem Cells: At the Headwaters of Tumor Development
Ward, R. J., & Dirks, P. B. (2007) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.2.010506.091847 · Cited by 164
Spindle Poisons and Cell Fate: A Tale of Two Pathways
Matson, D. R., & Stukenberg, P. T. (2011) · Molecular Interventions · doi:10.1124/mi.11.2.12 · Cited by 148
Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (Review)
Libra, M. (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.1312 · Cited by 142
Autophagy in tumorigenesis and cancer therapy: Dr. Jekyll or Mr. Hyde?
Zhou, S., Zhao, L., Kuang, M., Zhang, B., Liang, Z., Yi, T., Wei, Y., & Zhao, X. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.02.017 · Cited by 135
Acquired resistance to drugs targeting receptor tyrosine kinases
Rosenzweig, S. A. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.12.025 · Cited by 129
Tumour suppressor genes in chemotherapeutic drug response
Lai, D., Grieve, S., & Yang, X. (2012) · Bioscience Reports · doi:10.1042/bsr20110125 · Cited by 125
Tomicic, M. T., & Kaina, B. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.09.002 · Cited by 124
Non‐peptidic small molecule inhibitors against Bcl‐2 for cancer therapy
Azmi, A. S., & Mohammad, R. M. (2008) · Journal of Cellular Physiology · doi:10.1002/jcp.21567 · Cited by 123
The p53 Pathway as a Target in Cancer Therapeutics: Obstacles and Promise
Mandinova, A., & Lee, S. W. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001366 · Cited by 116
Cisplatin, camptothecin, and taxol sensitivities of cells with p53-associated multidrug resistance.
Vasey, P. A., Jones, N. A., Jenkins, S., Dive, C., & Brown, R. E. (1996) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09612-9 · Cited by 110
Targeting hypoxic tumour cells to overcome metastasis
Bennewith, K. L., & Dedhar, S. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-504 · Cited by 109
Chatterjee, M., Rancsó, C., Stühmer, T., Eckstein, N., Andrulis, M., Gerecke, C., Lorentz, H., Royer, H., & Bargou, R. C. (2007) · Blood · doi:10.1182/blood-2007-05-089151 · Cited by 109
Poly (ADP-Ribose) Polymerase as a Novel Therapeutic Target in Cancer
Annunziata, C. M., & O’Shaughnessy, J. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0526 · Cited by 105
Showalter, S. L., Showalter, T. N., Witkiewicz, A., Havens, R., Kennedy, E. P., Hucl, T., Kern, S. E., Yeo, C. J., & Brody, J. R. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.7.6181 · Cited by 104
Xia, C. Q., & Smith, P. G. (2012) · Molecular Pharmacology · doi:10.1124/mol.112.079129 · Cited by 103
pRB, a tumor suppressor with a stabilizing presence
Manning, A. L., & Dyson, N. J. (2011) · Trends in Cell Biology · doi:10.1016/j.tcb.2011.05.003 · Cited by 94
Deficient DNA Damage Signaling Leads to Chemoresistance to Cisplatin in Oral Cancer
Wang, L., Mosel, A., Oakley, G. G., & Peng, A. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0448 · Cited by 86
P53 and its molecular basis to chemoresistance in breast cancer
Knappskog, S., & Lønning, P. E. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.640322 · Cited by 82
Resistance to EGF-R (erbB-1) and VEGF-R modulating agents
Dempke, W. C. M., & Heinemann, V. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.11.038 · Cited by 78
Apoptosis In Targeted Therapy Responses
Faber, A. C., Ebi, H., Costa, C., & Engelman, J. A. (2012) · Advances in pharmacology · doi:10.1016/b978-0-12-397927-8.00016-6 · Cited by 72
Targeting the DNA damage response in oncology: past, present and future perspectives
Basu, B., Yap, T. A., Molife, L. R., & Bono, J. S. D. (2012) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32835280c6 · Cited by 68
5-Fluorouracil Pharmacogenomics: Still Rocking after all these years?
Scartozzi, M., Maccaroni, E., Giampieri, R., Pistelli, M., Bittoni, A., Prete, M. D., Berardi, R., & Cascinu, S. (2011) · Pharmacogenomics · doi:10.2217/pgs.10.167 · Cited by 67
Genes causing inherited cancer as beacons to identify the mechanisms of chemoresistance
Lønning, P. E. (2004) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.01.005 · Cited by 54
Mutant p53 proteins: Between loss and gain of function
Strano, S., Dell’Orso, S., Mongiovi, A. M., Monti, O., Lapi, E., Agostino, S. D., Fontemaggi, G., & Blandino, G. (2006) · Head & Neck · doi:10.1002/hed.20531 · Cited by 54
New insights into mechanisms of resistance to microtubule inhibitors
Ganguly, A., & Cabral, F. (2011) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2011.06.001 · Cited by 50
Baba, H., Teramoto, K., Kawamura, T., Mori, A., Imamura, M., & Arii, S. (2003) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-003-0695-8 · Cited by 20
Circumventing Melanoma Chemoresistance by Targeting DNA Repair
D, S. M. M., Bertazza, L., Benna, C., & Pilati, P. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712802002509 · Cited by 15
Farrell, A. (2011) · Nature Medicine · doi:10.1038/nm0311-262 · Cited by 11
Next-Generation cDNA Screening for Oncogene and Resistance Phenotypes
Shindoh, N., Yoda, A., Yoda, Y., Sullivan, T. J., Weigert, O., Lane, A. A., Kopp, N., Bird, L., Rodig, S. J., Fox, E. A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049201 · Cited by 9
Cited by
Breast cancer: Biology, biomarkers, and treatments
Barzaman, K., Karami, J., Zarei, Z., Hosseinzadeh, A., Kazemi, M. H., Moradi-Kalbolandi, S., Safari, E., & Farahmand, L. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106535 · Cited by 973
Nanomedicine therapeutic approaches to overcome cancer drug resistance
Markman, J. L., Rekechenetskiy, A., Holler, E., & Ljubimova, J. Y. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.019 · Cited by 733
“Cell cycle arrest does not occur when mutations, chromosomal rearrangements, and epigenetic changes are present, even when induced by anticancer therapies that induce DNA damage to cause cytotoxicity [30].”
BackgroundButti, R., Das, S., Gunasekaran, V. P., Yadav, A. S., Kumar, D., & Kundu, G. C. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0797-x · Cited by 390
Holbeck, S. L., Camalier, R., Crowell, J. A., Govindharajulu, J. P., Hollingshead, M., Anderson, L. W., Polley, E., Rubinstein, L., Srivastava, A., Wilsker, D., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0489 · Cited by 359
Doxorubicin resistance in breast cancer cells is mediated by extracellular matrix proteins
Lovitt, C. J., Shelper, T. B., & Avery, V. M. (2018) · BMC Cancer · doi:10.1186/s12885-017-3953-6 · Cited by 339
Metadata
- Authors
- Rebucci, M., & Michiels, C.
- Venue
- Biochemical Pharmacology
- Publisher
- Elsevier BV
- Published
- 2013-05
- Volume
- 85
- Issue
- 9
- Pages
- 1219-1226
- ISSN
- 0006-2952 (ISSN-L)
- OpenAlex
- W2015561372
- Cited by
- 407
- References
- 94
- FWCI
- 21.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.